Elan Corporation PLC

Elan Corporation, plc today announced that it will release the positive
Prialt(TM) Phase III trial results before the European and U.S. markets open on
Wednesday, January 7, 2004. Following the release, Elan will host a conference
call at 8:00am Eastern Standard Time (EST), 1:00pm Greenwich Mean Time (GMT)
with the investment community.

Live audio of the conference call will be simultaneously broadcast over the
Internet and will be available to investors, members of the news media and the
general public.

This event can be accessed by visiting Elan's website at www.elan.com and
clicking on the Investor Relations section, then on the event icon. The event
will be archived and available for replay after the call for 24 hours. The
replay telephone number is 800-633-8284 or 402-977-9140, reservation number
21180537.

About Elan

Elan is focused on the discovery, development, manufacturing, sale and marketing
of novel therapeutic products in neurology, severe pain and autoimmune diseases.
Elan (NYSE: ELN) shares trade on the New York, London and Dublin Stock
Exchanges.

    CONTACT: Elan Corporation
             Investors:
             Emer Reynolds, 353-1-709-4000
             800-252-3526
             or
             Media:
             Anita Kawatra, 212-407-5755
             800-252-3526